Jacobs Levy Equity Management
CLDX icon

Jacobs Levy Equity Management’s Celldex Therapeutics CLDX Stock Holding History

Jacobs Levy Equity Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-1,933
Closed -$15K – 998
2018
Q2 		$15K Sell
1,933
-15,074
-89% -$201K ﹤0.01% 1011
2018
Q1 		$594K Buy
17,007
+4,234
+33% +$164K 0.01% 750
2017
Q4 		$544K Buy
12,773
+5,026
+65% +$215K 0.01% 735
2017
Q3 		$332K Buy
7,747
+1,967
+34% +$73.7K 0.01% 772
2017
Q2 		$214K Buy
5,780
+1,673
+41% +$74K ﹤0.01% 824
2017
Q1 		$222K Buy
+4,107
New +$214K ﹤0.01% 773
2016
Q3 		– Sell
-9,127
Closed -$601K – 1026
2016
Q2 		$601K Sell
9,127
-53
-0.6% -$3.37K 0.01% 707
2016
Q1 		$521K Buy
+9,180
New +$1.03M 0.01% 715

Other funds holding CLDX

KE
KLP Enterprises Branford, Connecticut $1.97M AUM
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
TCMG
TSP Capital Management Group Summit, New Jersey $410M AUM 71.81% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return